Prescription of obesity treatment, ‘Contrave’ started, competing against ‘Belviq’

Since the prescription of ‘Contrave(naltrexone+bupropion),’ an obesity therapy whose domestic exclusive sales agreement was established by Kwang Dong Pharmaceutical, started this month, interests have been focused on the obesity treatment market.

As Contrave emerged as a rival of Ildong Pharmaceutical’s ‘Belviq(lorcaserin)’ which has played a crucial role for the depressed obesity treatment m...